IRRAS Stock Overview
IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IRRAS AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.16 |
| 52 Week High | SEK 0.63 |
| 52 Week Low | SEK 0.11 |
| Beta | 1.73 |
| 11 Month Change | -6.47% |
| 3 Month Change | -10.39% |
| 1 Year Change | -64.36% |
| 33 Year Change | -97.58% |
| 5 Year Change | -99.58% |
| Change since IPO | -99.57% |
Recent News & Updates
Recent updates
Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?
Dec 10
Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation
Jan 19We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully
Sep 22We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully
Apr 07Shareholder Returns
| IRRAS | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -1.1% | 0.6% | 1.6% |
| 1Y | -64.4% | 22.1% | 25.5% |
Return vs Industry: IRRAS underperformed the Swedish Medical Equipment industry which returned -10.8% over the past year.
Return vs Market: IRRAS underperformed the Swedish Market which returned 5.8% over the past year.
Price Volatility
| IRRAS volatility | |
|---|---|
| IRRAS Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.6% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: IRRAS has not had significant price volatility in the past 3 months.
Volatility Over Time: IRRAS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 47 | Will Martin | www.irras.com |
IRRAS AB (publ), a medical device company, focuses on the delivery of medical solutions to enhance the lives of critically ill patients worldwide. The company designs, develops, and commercializes neurocritical care products that transform patient outcomes and addresses complications associated with current treatment methodologies. It offers IRRAflow, an irrigating intracranial drainage system that combines controlled drainage, automated irrigation, and integrated monitoring of intracranial pressure (ICP) for the treatment of patients suffering from hemorrhagic strokes and chronic subdural hematoma.
IRRAS AB (publ) Fundamentals Summary
| IRRAS fundamental statistics | |
|---|---|
| Market cap | SEK 181.75m |
| Earnings (TTM) | -SEK 196.40m |
| Revenue (TTM) | SEK 43.10m |
4.2x
P/S Ratio-0.9x
P/E RatioIs IRRAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRRAS income statement (TTM) | |
|---|---|
| Revenue | SEK 43.10m |
| Cost of Revenue | SEK 44.03m |
| Gross Profit | -SEK 935.00k |
| Other Expenses | SEK 195.47m |
| Earnings | -SEK 196.40m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Feb 21, 2024
| Earnings per share (EPS) | -0.17 |
| Gross Margin | -2.17% |
| Net Profit Margin | -455.71% |
| Debt/Equity Ratio | 0% |
How did IRRAS perform over the long term?
See historical performance and comparison